WSA
BCRX icon

Wall Street Associates’s BioCryst Pharmaceuticals BCRX Stock Holding History

Wall Street Associates’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-56,269
Closed -$641K – 301
2015
Q3 		$641K Sell
56,269
-6,800
-11% -$90.7K 0.12% 197
2015
Q2 		$942K Buy
+63,069
New +$717K 0.09% 212

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wall Street Associates's BCRX Position: Q4 2015 in Review

Wall Street Associates sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2015, closing a stake of 56,269 shares — an estimated $641K sold.

Wall Street Associates first reported a position in BCRX in Q2 2015 and held it in 2 quarters. The position peaked at $942K in Q2 2015. 118 funds tracked by Wall St. Rank hold BCRX as of Q4 2015.

  • Wall Street Associates reported no remaining BioCryst Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Wall Street Associates sold 56,269 BioCryst Pharmaceuticals shares in Q4 2015, an estimated $641K.
  • Wall Street Associates first reported a position in BioCryst Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • Wall Street Associates's BioCryst Pharmaceuticals position peaked at $942K in Q2 2015.
  • 118 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2015.

Based on Wall Street Associates's 13F filing for Q4 2015, filed 11 Feb 2016.